Murepavadin
Also known as: Murepavadin, POL7080, RG7929
Source Murepavadin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Murepavadin (POL7080) is a synthetic cyclic peptide designed to treat serious Pseudomonas aeruginosa infections. Development halted after Phase II due to renal safety signals.
Mechanism of Action
Binds outer‑membrane protein LptD, blocking lipopolysaccharide transport and causing bacterial cell death in Pseudomonas aeruginosa
Routes of Administration
Goals & Uses
- Treatment of MDR/XDR Pseudomonas aeruginosa infectionsAntibacterial Therapy – Resistant PathogensModerate
- Inhaled therapy for pulmonary P. aeruginosa (e.g., cystic fibrosis)Infectious Disease / PulmonaryLow
- Treatment of Pseudomonas aeruginosa bloodstream infectionsAntibacterial TherapyModerate
- Ventilator-associated bacterial pneumonia (VABP)Infectious Disease / Critical CareModerate
- Hospital-acquired bacterial pneumonia (HABP)Infectious Disease / PulmonaryModerate
- Treatment of Pseudomonas aeruginosa infectionsAntibacterial TherapyModerate
- Ventilator‑associated pneumonia caused by P. aeruginosaAntibacterial TherapyModerate
Contraindications
- Known hypersensitivity to murepavadin or peptidomimetic componentsAllergy/ImmunologyHigh
- Severe pre-existing renal impairmentRenalHigh
- Severe renal impairmentOrganHighKidney function concerns
- Concurrent use of nephrotoxic agentsDrug Interaction / RenalHigh
- Known hypersensitivity to murepavadin or its excipientsAllergyModerate
Adverse Effects
- Acute kidney injury / NephrotoxicityRenalUncommon
- HeadacheNeurologicCommonPain in the head or upper neck
- Acute kidney injuryRenalUnknownSudden decline in kidney function
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- Elevated serum creatinineRenal / LaboratoryUncommon
- Elevated liver enzymesHepaticUncommonIncrease in AST/ALT or other hepatic markers
- Infusion-related reactionsHypersensitivityCommon
Drug Interactions
- Aminoglycosides (e.g., tobramycin, amikacin)High
- Concurrent nephrotoxic agents (e.g., aminoglycosides, vancomycin)High
- VancomycinHigh
- NSAIDsModerateMay increase renal risk in susceptible patients
- Colistin / Polymyxin BHigh
Population Constraints
- Patients with pre-existing renal impairmentOrgan FunctionRelative
- Pediatric patientsAgeRelative
- Pregnant or lactating womenReproductiveRelative
- Pregnant or breastfeeding womenReproductiveRelative
- Elderly patientsAgeRelative
Regulatory Status
- European UnionInvestigationalNo EMA approval; development halted.
- United StatesInvestigationalPhase II discontinued; no FDA approval.
- United KingdomInvestigationalNo MHRA approval; investigational only.
Development discontinued after reports of acute kidney injury; no regulatory approval in any jurisdiction.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Murepavadin?
Murepavadin (POL7080) is a synthetic cyclic peptide designed to treat serious Pseudomonas aeruginosa infections. Development halted after Phase II due to renal safety signals.
What is Murepavadin used for?
Murepavadin is educationally associated with: Treatment of MDR/XDR Pseudomonas aeruginosa infections, Inhaled therapy for pulmonary P. aeruginosa (e.g., cystic fibrosis), Treatment of Pseudomonas aeruginosa bloodstream infections, Ventilator-associated bacterial pneumonia (VABP), Hospital-acquired bacterial pneumonia (HABP), Treatment of Pseudomonas aeruginosa infections, Ventilator‑associated pneumonia caused by P. aeruginosa. Educational only — not medical advice.
How is Murepavadin administered?
Recorded routes of administration: Inhaled, Intravenous.
What are the potential side effects of Murepavadin?
Reported adverse effects include: Acute kidney injury / Nephrotoxicity, Headache, Acute kidney injury, Nausea, Elevated serum creatinine, Elevated liver enzymes, Infusion-related reactions. This list is not exhaustive — consult a qualified clinician.
Who should avoid Murepavadin?
Recorded contraindications: Known hypersensitivity to murepavadin or peptidomimetic components, Severe pre-existing renal impairment, Severe renal impairment, Concurrent use of nephrotoxic agents, Known hypersensitivity to murepavadin or its excipients. Consult a qualified clinician before use.